Kashiv BioSciences, announced the commercial launch of PEXEGRA, a biosimilar referencing Neulasta, and FILRA, a biosimilar referencing Neupogen, in the Canadian market. Both biosimilars will be marketed in Canada through an exclusive agreement with JAMP Pharma Corporation.
Health Technology Insights: AmeriPro Health Elects Larry Richardson as Board Chairman
PEXEGRA (6 mg/0.6 mL pre-filled syringe) and FILRA (300 mcg/0.5 mL and 480 mcg/0.8 mL pre-filled syringe) are used to treat neutropenia, low neutrophils which are a type of white blood cells that fight infection, which is commonly experienced by patients undergoing chemotherapy. As per IQVIA, Canada sales of Filgrastim and Pegfilgrastim were ~57 Mn USD and ~87 Mn USD, respectively for MAT June 2025. Global sales of Filgrastim and Pegfilgrastim were ~1.2 Bn USD and ~3.1 Bn USD, respectively for MAT June 2025.
Sandeep Athalye, Chief Executive Officer of Kashiv Biosciences said, “We are delighted to bring PEXEGRA and FILRA to patients in Canada. Kashiv’s facilities are fully prepared to support JAMP’s commercialization efforts, and we look forward to working together to expand access to high-quality, affordable biosimilars worldwide.”
Health Technology Insights: Julius Clinical Welcomes Bassem Saleh as Chief Executive Officer
Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets and is among the few U.S.-based companies to both manufacture and receive marketing authorization for multiple biosimilars. Kashiv BioSciences, LLC in the USA, and its subsidiaries in India operate together with robust infrastructure and highly skilled teams that provide global R&D, clinical, manufacturing, regulatory, and IP capabilities. We believe our people, partners, and shared purpose fuel our work to advance patient care and access to important medicines.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 23 September 2025
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
